Archives de l’auteur : osivax

OSIVAX appoints Dr. W. Ripley Ballou (M.D) as member of its Clinical Advisory Board

Rip Ballou’s appointment will strengthen OSIVAX’s ambition to develop a pipeline of disruptive vaccines against infectious diseases. Lyon, France – September 22, 2021 – OSIVAX, a biopharmaceutical company focused on the development of “universal” vaccines against mutating viruses, including influenza and coronaviruses, announced today the appointment of Dr. Ripley Ballou (MD) as member of its Clinical …

Continuer la lecture « OSIVAX appoints Dr. W. Ripley Ballou (M.D) as member of its Clinical Advisory Board »

Osivax announces Last Subject Last Visit completed in Phase 2a Clinical Trial of OVX836 Universal Influenza Vaccine Candidate

Osivax announces Last Subject Last Visit completed in Phase 2a Clinical Trial of OVX836 Universal Influenza Vaccine Candidate — Full immunogenicity and safety results expected for early 2021 –Lyon, France – September 10, 2020 –Osivax announced today that the Last Subject’s Last Visit (LSLV) occurred in the Phase 2a clinical trial of OVX836 universal Influenza …

Continuer la lecture « Osivax announces Last Subject Last Visit completed in Phase 2a Clinical Trial of OVX836 Universal Influenza Vaccine Candidate »

OSIVAX Announces Completion of Enrolment in its Phase 2a Clinical Trial of OVX836 Universal Influenza Vaccine Candidate

OSIVAX Announces Completion of Enrolment in its Phase 2a Clinical Trial of OVX836 Universal Influenza Vaccine Candidate —  Top line results expected by the first quarter of 2021 —Lyon, France – April 09, 2020 – OSIVAX, a clinical stage biopharmaceutical company currently focusing on the development of a universal influenza vaccine candidate, announced today that it completed …

Continuer la lecture « OSIVAX Announces Completion of Enrolment in its Phase 2a Clinical Trial of OVX836 Universal Influenza Vaccine Candidate »

Osivax Announces First Volunteers Enrolled in Phase 2a clinical trial of OVX836 Universal Influenza Vaccine Candidate

Osivax Announces First Volunteers Enrolled in Phase 2a clinical trial of OVX836 Universal Influenza Vaccine Candidate —  Phase 2a clinical trial on 300 healthy volunteers run under US IND —Lyon, France – January 21, 2020 – OSIVAX, a clinical stage biopharmaceutical company currently focused on the development of a universal influenza vaccine candidate, enrolled the first participant in …

Continuer la lecture « Osivax Announces First Volunteers Enrolled in Phase 2a clinical trial of OVX836 Universal Influenza Vaccine Candidate »

Osivax Enters Agreement with U.S. National Institutes of Health to Test Universal Flu Vaccine Candidate

Osivax Enters Agreement with U.S. National Institutes of Health to Test Universal Flu Vaccine Candidate Lyon, France – December 5, 2019 – Osivax announced today that it has entered into an agreement with the United States’ National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to further advance the development …

Continuer la lecture « Osivax Enters Agreement with U.S. National Institutes of Health to Test Universal Flu Vaccine Candidate »

Osivax Extends Executive Team to Strengthen Corporate Expansion and Accelerate the Development of Universal Flu Vaccine Candidate

Osivax Extends Executive Team to Strengthen Corporate Expansion and Accelerate the Development of Universal Flu Vaccine Candidate​— Linda Lebon joins as Chief Regulatory Officer —— Florian Sourd joins as VP Finance — Lyon, France – October 30th, 2019 – Osivax announced today the appointment of Linda Lebon as Chief Regulatory Officer and Florian Sourd as VP …

Continuer la lecture « Osivax Extends Executive Team to Strengthen Corporate Expansion and Accelerate the Development of Universal Flu Vaccine Candidate »